Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
ID: ALA477147
Max Phase: Preclinical
Molecular Formula: C25H27N3O4
Molecular Weight: 433.51
Molecule Type: Small molecule
Associated Items:
ID: ALA477147
Max Phase: Preclinical
Molecular Formula: C25H27N3O4
Molecular Weight: 433.51
Molecule Type: Small molecule
Associated Items:
Canonical SMILES: O=C[C@H](C[C@@H]1CCNC1=O)NC(=O)[C@H](Cc1ccccc1)NC(=O)/C=C/c1ccccc1
Standard InChI: InChI=1S/C25H27N3O4/c29-17-21(16-20-13-14-26-24(20)31)27-25(32)22(15-19-9-5-2-6-10-19)28-23(30)12-11-18-7-3-1-4-8-18/h1-12,17,20-22H,13-16H2,(H,26,31)(H,27,32)(H,28,30)/b12-11+/t20-,21-,22-/m0/s1
Standard InChI Key: GLPMVVAUDLVTNQ-QENTWVPSSA-N
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
Molecule Type: Small molecule | Topical: No | First In Class: No | Black Box: No |
Chirality: No | Availability: No | Prodrug: No |
MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
---|
Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
---|
Molecular Weight: 433.51 | Molecular Weight (Monoisotopic): 433.2002 | AlogP: 1.64 | #Rotatable Bonds: 10 |
Polar Surface Area: 104.37 | Molecular Species: NEUTRAL | HBA: 4 | HBD: 3 |
#RO5 Violations: 0 | HBA (Lipinski): 7 | HBD (Lipinski): 3 | #RO5 Violations (Lipinski): 0 |
CX Acidic pKa: 12.65 | CX Basic pKa: | CX LogP: 1.69 | CX LogD: 1.69 |
Aromatic Rings: 2 | Heavy Atoms: 32 | QED Weighted: 0.39 | Np Likeness Score: 0.45 |
1. Kuo CJ, Shie JJ, Fang JM, Yen GR, Hsu JT, Liu HG, Tseng SN, Chang SC, Lee CY, Shih SR, Liang PH.. (2008) Design, synthesis, and evaluation of 3C protease inhibitors as anti-enterovirus 71 agents., 16 (15): [PMID:18583140] [10.1016/j.bmc.2008.06.015] |
2. Zhai Y, Zhao X, Cui Z, Wang M, Wang Y, Li L, Sun Q, Yang X, Zeng D, Liu Y, Sun Y, Lou Z, Shang L, Yin Z.. (2015) Cyanohydrin as an Anchoring Group for Potent and Selective Inhibitors of Enterovirus 71 3C Protease., 58 (23): [PMID:26571192] [10.1021/acs.jmedchem.5b01013] |
3. Dai W, Jochmans D, Xie H, Yang H, Li J, Su H, Chang D, Wang J, Peng J, Zhu L, Nian Y, Hilgenfeld R, Jiang H, Chen K, Zhang L, Xu Y, Neyts J, Liu H.. (2022) Design, Synthesis, and Biological Evaluation of Peptidomimetic Aldehydes as Broad-Spectrum Inhibitors against Enterovirus and SARS-CoV-2., 65 (4.0): [PMID:33872498] [10.1021/acs.jmedchem.0c02258] |
Source(1):